Table of Contents
Overview
Definition and Scope
Molecular medicine is defined as an applied science that focuses on human genes, transcripts, proteins, metabolites, and metabolic networks, elucidating the molecular and cellular processes involved in health and the onset and progression of diseases.[1.1] This field aims to bridge the gap between laboratory research and clinical practice, updating physicians on advancements that may influence bedside medicine.[2.1] The scope of molecular medicine encompasses various overlapping disciplines, including molecular biology, which utilizes DNA-based knowledge for research, and genetic engineering or recombinant DNA (rDNA) technology, which applies this knowledge to develop new products in both industry and research.[3.1] The evolution of molecular medicine can be categorized into three significant periods: the discovery of DNA structure in 1953 and subsequent developments in rDNA technologies; the Human Genome Project, which spanned from 1990 to 2000; and the emergence of omics technologies.[3.1] Historically, the foundation of molecular medicine was laid in November 1949 with the publication of "Sickle Cell Anemia, a Molecular Disease" by Linus Pauling and his collaborators, which established the field's principles.[4.1] Further contributions, such as Roger J. Williams' 1956 work "Biochemical Individuality," emphasized the genetic basis of disease prevention and treatment, leading to concepts now recognized as individualized and orthomolecular medicine.[4.1] The completion of the Human Genome Project has significantly advanced the field, providing a comprehensive sequence of the human genome and revealing critical insights pertinent to molecular medicine.[5.1]Importance in Modern Healthcare
Molecular medicine plays a crucial role in modern healthcare by facilitating the transition from traditional, one-size-fits-all treatment approaches to more personalized strategies that consider individual genetic profiles. This shift is largely driven by advancements in genomics and biotechnology, which enable healthcare providers to predict disease risks and tailor treatments accordingly. Personalized medicine leverages integrated molecular information to enhance precision in diagnosis and treatment strategies, ultimately improving patient outcomes.[13.1] The integration of genetic testing into clinical practice has significant implications for treatment strategies. For instance, the use of genomics in personalized medicine allows for the identification of specific genetic variations that influence an individual's susceptibility to diseases and their response to various therapies. This capability not only enhances the effectiveness of treatments but also minimizes adverse effects by ensuring that patients receive therapies best suited to their unique genetic makeup.[12.1] Moreover, the rise of precision medicine is accompanied by ethical considerations, particularly regarding the privacy and security of genetic data. As genetic testing becomes more prevalent, concerns about potential discrimination by insurance companies and employers arise, necessitating robust ethical frameworks to protect individuals' rights while promoting public health initiatives.[11.1] Effective communication of these ethical implications is essential to ensure informed consent and understanding among patients, thereby fostering trust in genetic testing practices.[10.1] In addition to ethical challenges, the clinical translation of genomic medicine faces hurdles related to the integration of multi-omics data and the need for interdisciplinary collaboration. Successful implementation requires the synthesis of various fields, including bioinformatics, epidemiology, and clinical research, to create high-resolution disease models that can inform personalized treatment plans.[15.1] As the field continues to evolve, the potential for molecular medicine to provide novel diagnostic and therapeutic solutions for complex diseases remains a promising frontier in healthcare.[14.1]In this section:
History
Key Milestones in Molecular Medicine
The history of molecular medicine is marked by several key milestones that have significantly advanced the field. One of the earliest and most pivotal moments occurred in 1869 when Friedrich Miescher discovered DNA, laying the foundational stones for modern molecular biology and marking a significant turning point in genetics. This discovery shifted the understanding of heredity from classical Mendelian genetics to a more comprehensive molecular perspective, influencing biological research profoundly.[41.1] In 1953, James Watson and Francis Crick unveiled the double helix structure of DNA, a revelation that transformed molecular biology and established the genetic blueprint for life. This discovery not only advanced molecular biology but also opened new avenues for understanding heredity and disease, thereby influencing the development of molecular medicine as a discipline.[43.1] Following this, the 1949 publication of the paper "Sickle Cell Anemia, a Molecular Disease" by Linus Pauling and colleagues is widely regarded as the starting point for the emergence of molecular medicine as a distinct field, establishing sickle cell anemia as a genetic condition.[42.1] The subsequent decades saw significant advancements, including the emergence of recombinant DNA (rDNA) technologies in the 1970s, which allowed for the manipulation of genetic material and paved the way for innovations in genetic engineering.[38.1] The Human Genome Project, conducted from 1990 to 2000, further propelled the field by mapping the entire human genome, enhancing the understanding of genetic diseases and their molecular underpinnings.[38.1] In the 21st century, molecular medicine has continued to evolve with the introduction of precision medicine initiatives, CRISPR-Cas9 gene editing technologies, and advancements in liquid biopsies for cancer detection. These innovations have not only improved disease diagnosis and treatment but have also raised ethical considerations regarding gene patenting and public perceptions of genetic manipulation.[47.1] The ongoing development of functional genomics and genomic epidemiology further underscores the dynamic nature of molecular medicine, as it continues to identify therapeutic targets and track disease outbreaks.[36.1]Recent Advancements
Precision Medicine
In 2023, significant advancements in precision medicine have emerged, particularly through the application of innovative therapies and technologies. One of the most notable breakthroughs was the U.S. FDA's awarding of breakthrough therapy designation to a combination of a personalized mRNA vaccine (mRNA-4157/V940) and the monoclonal antibody pembrolizumab for the adjuvant treatment of high-risk melanoma following complete resection. This development underscores the potential of personalized medicine to enhance treatment efficacy in oncology.[81.1] Additionally, the introduction of the gene therapy CASGEVY, which corrects faulty hemoglobin genes in patients with sickle cell disease and beta thalassemia, represents a transformative approach in treating genetic disorders. This therapy has the potential to cure some patients for life with a single treatment, highlighting the promise of precision medicine in addressing complex genetic conditions.[82.1] The year also marked the approval of the first CRISPR/Cas9 gene-editing therapy, which is poised to revolutionize the treatment of genetic diseases. This technology allows for precise targeting and editing of genes, facilitating advancements in the treatment of conditions such as β-thalassemia and severe sickle cell disease through clinical trials involving CRISPR-edited human stem cells.[88.1] Furthermore, CRISPR/Cas9 has been utilized in cancer research, demonstrating its capability to identify new drug targets and elucidate mechanisms of drug resistance, thereby enhancing the precision of cancer therapies.[87.1] Moreover, the development of new vaccines, including those for respiratory syncytial virus (RSV) and the Alzheimer's drug lecanemab, reflects a broader trend in precision medicine aimed at tailoring interventions to individual patient needs and disease mechanisms.[89.1] These advancements collectively illustrate the ongoing evolution of precision medicine, which is increasingly focused on personalized approaches to treatment and prevention, thereby promising to transform healthcare outcomes in the coming years.[85.1]Applications In Medicine
Targeted Therapies
Targeted therapies represent a significant advancement in the field of molecular medicine, focusing on the precise classification of diseases and the stratification of patients based on their unique molecular profiles. This approach facilitates the implementation of tailored therapeutic strategies, maximizing treatment efficacy while minimizing adverse effects.[124.1] Molecular therapeutics encompasses a broad spectrum of methods that leverage our understanding of molecular pathways, genetics, and biomarkers to develop targeted treatments for various diseases, including cancer, autoimmune disorders, and rare genetic diseases.[124.1] The evolution of targeted therapies has been particularly transformative in oncology, where they have provided more personalized and effective treatment options compared to traditional therapies. For instance, gene therapies and nucleic acid-based drugs specifically target the genetic underpinnings of diseases, allowing for interventions that are more aligned with the individual patient's molecular makeup.[123.1] This shift towards personalized medicine is further supported by advancements in drug delivery systems, which are designed to enhance the precision of therapeutic agents, ensuring they reach the intended target sites within the body.[134.1] Moreover, the integration of molecular biology into medical practice has revolutionized diagnostic methods and therapeutic approaches. By analyzing and manipulating genes and proteins, molecular biology has not only improved patient outcomes but has also paved the way for innovative treatments that address the molecular mechanisms of diseases.[125.1] As the field continues to evolve, emerging technologies such as nanomedicine and gene editing hold immense potential for further enhancing the effectiveness of targeted therapies.[123.1]Genetic Testing
Genetic testing plays a crucial role in the diagnosis, prognosis, and treatment of various diseases, particularly in the fields of cancer, cardiovascular disorders, and rare genetic conditions. The integration of genomic data into clinical practice has been shown to enhance clinical decision-making and improve patient outcomes, especially given that approximately 80% of rare diseases have a genetic component.[144.1] For instance, the development of the pRARE (Personalized Rare Diseases Exome) panel in Andalusian hospitals exemplifies how tailored genomic testing can facilitate personalized treatment strategies and improve the management of complex diseases.[144.1] Moreover, advancements in artificial intelligence (AI) and machine learning (ML) have significantly contributed to the field of rare disease genomics. These technologies assist in analyzing vast amounts of genomic and clinical data, thereby identifying disease patterns, predicting treatment outcomes, and developing personalized therapies.[145.1] AI's role extends to utilizing data from patient registries to uncover associations that enhance prevention, diagnosis, treatment, and monitoring based on individual genetic profiles.[146.1] However, challenges remain in the integration of these technologies into routine clinical practice, including issues related to data quality, algorithm interpretability, and regulatory concerns.[146.1] In the United States, initiatives like the eMERGE (Electronic Medical Records and genomics) project have been established to integrate genomic data into electronic health records (EHRs). This project aims to utilize genetic test results in clinical and pharmaceutical research, highlighting the importance of a structured approach to incorporating genetic information into healthcare systems.[147.1] The successful integration of genomic data into EHRs requires addressing various technical and functional requirements, ensuring that healthcare providers can effectively utilize this information in patient care.[147.1]In this section:
Ethical Considerations
Genetic Privacy
The ethical considerations surrounding genetic privacy in molecular medicine are paramount, particularly as genomic research increasingly intersects with clinical applications. Protecting the privacy of research participants is essential, as it involves sensitive genetic information that could have broader societal implications. The National Institutes of Health (NIH) has established a controlled-access model to safeguard participants against re-identification risks, which can arise even from de-identified data.[196.1] This model is part of a broader framework that aligns with federal regulations, including the NIH's Genomic Data Sharing (GDS) Policy and the Genetic Information and Nondiscrimination Act of 2008 (GINA), which collectively aim to protect the genetic privacy of individuals involved in research.[199.1] Informed consent is a critical component of maintaining participant privacy, particularly in the context of next-generation sequencing (NGS) technologies. Researchers must ensure that participants are adequately informed about the privacy risks associated with data sharing and the potential for re-identification.[198.1] This includes discussing the implications of both positive and negative test results, as well as the protections in place for their information.[198.1] Moreover, the NIH's Policy for Data Management and Sharing (DMS) provides a set of principles and best practices designed to create a robust framework for protecting participant privacy when sharing data.[199.1] These guidelines emphasize the importance of ethical data stewardship, balancing the need for data sharing to advance research with the imperative to protect participant confidentiality.[183.1] Challenges in data sharing also highlight the need for careful consideration of privacy risks, particularly in the context of genomic research. Researchers are encouraged to adopt a bidirectional framework for evaluating privacy risks associated with shared data, focusing on re-identification risks such as membership inference attacks.[186.1] This structured approach is vital for ensuring that data sharing practices do not undermine the trust of vulnerable populations in the clinical trial process.[185.1] Ultimately, the development of effective policies for genomic and clinical data sharing requires collaboration among experts in various fields, including computer science, ethics, and privacy law, to ensure that the privacy of individuals is respected while facilitating efficient data analysis in biomedical research.[196.1]Informed Consent
Informed consent is a fundamental principle in molecular medicine, ensuring that patients are fully aware of the implications of their participation in research and treatment. It is essential that patients receive comprehensive information about the proposed research or medical procedures, enabling them to make autonomous decisions regarding their care.[170.1] The complexity of molecular diagnostics and genetic testing introduces unique challenges in the informed consent process, particularly regarding the understanding of genetic data and its potential implications beyond the individual participant.[168.1] To enhance the informed consent process, healthcare providers are encouraged to adopt a communication-centered approach rather than viewing consent merely as a signature on a form.[171.1] This involves presenting information in a clear and accessible manner, which is crucial for patient comprehension.[170.1] Additionally, the integration of technology can facilitate better understanding and engagement among patients, thereby improving the overall informed consent experience.[172.1] Research indicates that trust plays a significant role in patients' willingness to participate in genomic studies, highlighting the need for transparent communication about the collection and use of genetic data.[169.1] Ethical considerations surrounding informed consent also encompass issues of privacy, data sharing, and the potential risks associated with genetic research.[165.1] As the field of molecular medicine continues to evolve, ensuring that patients provide informed consent will be increasingly important, particularly in areas such as hematology where genetic testing is becoming more prevalent.[168.1]In this section:
Future Directions
Emerging Technologies
Emerging technologies in molecular medicine are significantly reshaping the landscape of healthcare, particularly through advancements in molecular biology, exposomics, and genetic research. Molecular biology has been pivotal in enhancing our understanding of genetic material and protein synthesis, which is crucial for the development of personalized medicine. This field has enabled the identification of molecular pathways and genetic variations that influence disease susceptibility and treatment responses, thereby facilitating the creation of targeted therapies tailored to individual patients.[205.1] Exposomics, an emerging discipline that studies the totality of environmental exposures, is also contributing to molecular medicine by elucidating how these exposures affect cellular and molecular processes, including gene expression and immune responses. This understanding can lead to more effective interventions and personalized treatment strategies.[203.1] Furthermore, the integration of genetic data into clinical practice is revolutionizing patient care. By employing genetic testing, healthcare providers can predict drug efficacy and tailor treatments to align with patients' unique genetic profiles, enhancing treatment outcomes and minimizing adverse effects.[207.1] Pharmacogenetics, which examines the genetic determinants of drug response variability, is gaining traction as personalized medicine programs increasingly incorporate preemptive genotyping of pharmacogenetic variants. This approach allows for more informed clinical decisions and the potential for improved patient outcomes through personalized drug therapies.[206.1] Additionally, the mainstreaming of genetic testing, particularly whole genome sequencing, is becoming a standard practice in healthcare, further emphasizing the importance of genomics in diagnosing and treating rare diseases and cancers.[207.1] As these technologies advance, ethical considerations surrounding their application, particularly in gene editing, must also be addressed. The use of CRISPR and other gene editing technologies presents opportunities for targeted disease intervention but raises significant ethical questions regarding the implications of germline editing and the need for regulatory frameworks to ensure responsible use.[221.1] Balancing innovation in personalized treatments with the ethical obligation to protect patient privacy is essential as genomic data becomes increasingly integral to molecular medicine.[210.1]In this section:
References
[1] Molecular Medicine - IntechOpen — Molecular medicine is an applied science focused on human genes/transcripts, proteins, metabolites, and metabolic networks that describes molecular and cellular processes of health and disease onset and progression. ... Principally, Molecular Medicine provides an overview of the latest headlines/developments of systems and molecular medicine
[2] Molecular medicine--an overview - PubMed — Molecular medicine--an overview Isr Med Assoc J. 2002 Aug;4(8):638-40. Authors Shai Izraeli 1 , Gideon Rechavi. Affiliation 1 ... The aim of this series of review on different aspects of molecular medicine is to update physicians on new advances at the bench that are likely to impact bedside medicine. Publication types
[3] Molecular Medicine - an overview | ScienceDirect Topics — Other terms that overlap with molecular medicine include molecular biology (the use of DNA-based knowledge in research), genetic engineering or recombinant DNA (rDNA) technology (the use of DNA-based knowledge for new products in industry or research). Other terms that overlap with molecular medicine include molecular biology (the use of DNA-based knowledge in research), genetic engineering or recombinant DNA (rDNA) technology (the use of DNA-based knowledge for new products in industry or research). The emergence of molecular medicine may broadly be considered over three time periods: (1) The discovery of DNA structure in 1953 followed by developments in recombinant DNA (rDNA) technologies; (2) The Human Genome Project 1990–2000, and (3) The launch of omics (Figure 1.1).
[4] Molecular medicine - Wikipedia — Molecular medicine In November 1949, with the seminal paper, "Sickle Cell Anemia, a Molecular Disease", in Science magazine, Linus Pauling, Harvey Itano and their collaborators laid the groundwork for establishing the field of molecular medicine. In 1956, Roger J. Williams wrote Biochemical Individuality, a prescient book about genetics, prevention and treatment of disease on a molecular basis, and nutrition which is now variously referred to as individualized medicine and orthomolecular medicine. Another paper in Science by Pauling in 1968, introduced and defined this view of molecular medicine that focuses on natural and nutritional substances used for treatment and prevention. Molecular surgery[edit] ^ BJ Strasser, Perspectives: Molecular Medicine, [ "Sickle Cell Anemia, a Molecular Disease"] Science, 19 November 1999, vol.
[5] PDF — In essence, molecular medicine is genetic medicine. Since the publication of the first edition Principles of Molecular Medicine in 1998, the Human Genome Project has provided a "complete" sequence of the human genome with several surprising revelations relevant to molecular medicine.
[10] Communicating about Genes, Health, and Risk | Oxford Research ... — Communication about genes, health, and risk may induce genetic essentialist beliefs when messages highlight the role of genetics and ignore the role of environmental toxins in disease, and when there are images containing racial and ethnic content. With an increasing number of diseases being related to genetic contributors, media framing associated with communicating about genes, health, and risk issues together with the accessibility of information about the role of genes in illness susceptibility is increasingly important. Journal of Health Communication, 13, 808–823. Journal of Health Communication, 5, 29–39. Journal of Health Communication, 17, 762–778. Journal of Health Communication, 19(7), 838–852. Health Communication, 29, 483–493. Journal of Health Communication, 11, 1–17. Journal of Health Communication, 15, 76–94.
[11] A double-edged helix: The ethical consequences of widespread genetic ... — Nevertheless, as genetic testing becomes more widespread, the storage of genetic data presents significant ethical and security challenges, prompting critical questions: Are current storage methods truly capable of safeguarding such sensitive information? Before examining these risks, we must first explore the ethical dilemmas that persist even when genetic testing and data management adhere to the highest security standards. Autonomy ensures that patients give informed consent and fully understand the purpose, benefits, and risks of genetic testing while also maintaining control over which results are disclosed, including unexpected findings. A breach of genetic data could result in unofficial blacklists where high-risk individuals find themselves unable to access essential coverage even if they never develop the disease.
[12] (Pdf) Advances in Personalized Medicine: Harnessing Genomics and ... — (PDF) ADVANCES IN PERSONALIZED MEDICINE: HARNESSING GENOMICS AND PRECISION THERAPEUTICS ADVANCES IN PERSONALIZED MEDICINE: HARNESSING GENOMICS AND PRECISION THERAPEUTICS The integration of precision therapies and genomics has transformed the field of personalized medicine. KEYWORDS: Personalized medicine, genomics, precision therapeutics, variations associated with diseases and drug responses. Personalized medicine is a patient- Carlsten C, Brauer M, Brinkman F, Brook J, Daley D, McNagny K, et al. These data indicate that we can use integrated molecular information from cancer databases to predict drug responsiveness in individual patients and thus enable precision medicine. This review will discuss the current environment of precision medicine, including clinically approved targeted therapies, the latest potential therapeutic agents, and the ongoing pharmacogenetic trials for CRC patients.
[13] Revolutionizing Personalized Medicine: Synergy with Multi-Omics Data ... — The history of personalized medicine is punctuated by significant milestones in genetics, technology, and clinical applications, shifting healthcare from a one-size-fits-all approach to a more individualized understanding of the molecular basis of health and disease and effective treatment strategies . Advances in genomics and biotechnology in the 21st century are enabling more personalized approaches to medicine, predicting disease risks, and tailoring treatments to individual genetic profiles. Personalized medicine leverages these images in conjunction with genetic data to gain deeper insights into disease mechanisms in individual patients, enhancing precision in diagnosis and treatment strategies . Through the integration of genetic, molecular, and clinical data, personalized medicine enables more accurate diagnosis, precise treatment targeting, and effective disease management.
[14] Integrating computational biology and multiomics data for precision ... — Integrating computational biology and multiomics data for precision medicine in personalized cancer treatment - ScienceDirect Chapter 14 - Integrating computational biology and multiomics data for precision medicine in personalized cancer treatment In the pursuit of advancing personalized cancer treatment, this research explores the integration of computational biology methodologies with multiomics data analysis. Through the integration of computational biology and multiomics data, this research endeavors to propel the paradigm of precision medicine toward a more refined and individualized approach in the realm of cancer therapeutics. Copyright © 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies. Brawley, …, Sara R. For all open access content, the Creative Commons licensing terms apply.
[15] Translating genomic medicine to the clinic: challenges and ... — Genomic medicine has considerable potential to provide novel diagnostic and therapeutic solutions for patients who have molecularly complex diseases and who are not responding to existing therapies. These promising developments have led to several efforts aimed at implementing genomic medicine in clinical practice for early disease detection or molecularly tailored treatments. In summary, we propose that the clinical translation of genomic medicine will require the integration of multi-omics and clinical data and that emerging technologies such as single-cell approaches may facilitate the construction of high-resolution disease models. Bridging that gap involves addressing several different challenges: from a research perspective, the clinical translation of genomic medicine requires the integration of multiple disciplines, such as omics, epidemiology, bioinformatics, and experimental and clinical research.
[36] Revolutionizing Medical Microbiology: How Molecular and Genomic ... — YearMilestone1949Introduction of the term "molecular disease" by Pauling et al., linking a single amino acid change to sickle cell anemia1980 Recommendation of a prenatal genetic test for thalassemia based on restriction enzymes cutting DNA at specific sequences1980’sThe emergence of companies like Molecular Diagnostics Incorporated and Bethesda Research Laboratories Molecular Diagnostics1990’sIdentification of newly discovered genes and development of new techniques for DNA sequencing1995Formation of the Association for AMP1998The European Union's Directive 98/44/EC allows patents on DNA sequences.1999Co-founding of The Journal of Medical Diagnostics by AMP2001Launch of Expert Reviews in Medical Diagnostics by Informa Healthcare2002Commencement of the Hap Map Project to study genetic differences in the human population2010The lawsuit by AMP against Myriad Genetics over gene patents related to BRCA1 and BRCA22012Molecular diagnostic techniques for thalassemia utilize genetic hybridization tests.2013The US Supreme Court ruled that naturally occurring gene sequences cannot be patented.2015CRISPR-Cas9 gene editing, precision medicine initiatives, and liquid biopsies for cancer detection2018Single-cell RNA sequencing and liquid biopsies for cancer detection2020Genomic epidemiology tracks and contains outbreaks.2022Functional genomics identifies therapeutic targets.
[38] Molecular Medicine - an overview | ScienceDirect Topics — Other terms that overlap with molecular medicine include molecular biology (the use of DNA-based knowledge in research), genetic engineering or recombinant DNA (rDNA) technology (the use of DNA-based knowledge for new products in industry or research). Other terms that overlap with molecular medicine include molecular biology (the use of DNA-based knowledge in research), genetic engineering or recombinant DNA (rDNA) technology (the use of DNA-based knowledge for new products in industry or research). The emergence of molecular medicine may broadly be considered over three time periods: (1) The discovery of DNA structure in 1953 followed by developments in recombinant DNA (rDNA) technologies; (2) The Human Genome Project 1990–2000, and (3) The launch of omics (Figure 1.1).
[41] The Pioneering Discoveries of Friedrich Miescher: Unveiling the Secrets ... — The Pioneering Discoveries of Friedrich Miescher: Unveiling the Secrets of Nucleic Acids - BioPathogenix The Pioneering Discoveries of Friedrich Miescher: Unveiling the Secrets of Nucleic Acids His work laid the foundation for understanding the role of nucleic acids in heredity and cell function, influencing countless researchers and advancing the field of genetics. The Lasting Impact of Friedrich Miescher’s Discovery of Nucleic Acids Friedrich Miescher’s discovery of nucleic acids has had profound and far-reaching implications in modern science and medicine. Genetic Research and Biotechnology: Miescher’s identification of nucleic acids laid the foundation for the field of genetics. Miescher’s pioneering research continues to be a cornerstone of modern science, influencing a wide range of fields and driving innovations that improve our understanding of life and our ability to address complex biological challenges.
[42] 6 PIONEERS OF MOLECULAR MEDICINE - University of Mississippi Medical Center — A leading member of the group of researchers who published the groundbreaking paper “Sickle Cell Anemia, a Molecular Disease” in 1949, Pauling has been called the “founding father of molecular biology.” That paper, which established that sickle cell anemia was a genetic condition, is widely regarded as the starting point for the emergence of molecular medicine as a distinct field. Continuing the work of the trailblazers featured here, we at the University of Mississippi Medical Center are actively contributing to significant research in molecular medicine. Led by primary faculty from UMMC’s School of Graduate Studies in the Health Sciences, our Program is designed to equip you for diverse and fulfilling careers in healthcare, including molecular medicine and beyond. For further details or to apply to UMMC’s online Molecular Medicine Graduate Certificate Program, visit our website now!
[43] Celebrating 70 years of DNA discovery: exploring the Blueprint of Life — After publishing their model, Watson and Crick quickly expanded upon it by providing more precise descriptions of the structure of DNA and its genetic implications . Watson, Crick, and Wilkins were honored with the Nobel Prize in Physiology or Medicine in 1962 for their groundbreaking research on the molecular structure of nucleic acids and their role in transmitting information within living organisms. Initially, the concept that chromosomes contain genetic material composed of nucleic acid rather than proteins emerged through mutation studies on various organisms like Sphaerocarpus donnellii liverwort, microbial fungi, and maize. The discovery of the DNA stands out as one of the greatest feats in scientific history, forever changing our view on genetics and life’s building blocks.
[47] U.S. public opinion about the safety of gene editing in the agriculture ... — Introduction: Implementation of gene editing in agriculture and medicine hinges on public acceptance. The objectives of this study were to explore U.S. public opinion about gene editing in agricultural and medical fields and to provide more insight into the relationship between opinions about the safety of gene editing and the potential impact of evidence to improve opinions about safety.
[81] 2023's most exciting medical research breakthroughs - MDLinx — In February 2023, the US FDA awarded breakthrough therapy designation to the combination of a personalized mRNA vaccine (mRNA-4157/V940) and a monoclonal antibody (pembrolizumab) for adjuvant treatment of patients with high-risk melanoma following complete resection. ... Malkas is a professor at City of Hope's Department of Molecular
[82] 7 medical breakthroughs that gave us hope in 2023 - National Geographic — Aside from COVID-19 vaccines, there were many other interesting and groundbreaking discoveries made this year, some of which are especially notable for their potential impact on health and medicine. It treats sickle cell disease and beta thalassemia, genetic disorders that affect the red blood cells. The newly approved gene therapy, named CASGEVY, corrects faulty hemoglobin genes in a patient’s bone marrow stem cells so they can produce functioning hemoglobin. A single treatment can potentially cure some patients for life.
[85] The top biotech breakthroughs that defined 2023 — As we look back at 2023 it is clear that the year has been marked by steady progress and notable breackthroughts in the biotech industry. From advancements in Alzheimer’s disease treatments to new approaches in cancer therapy, artificial intelligence (AI) progression, and obesity management, this year has seen important steps forward in healthcare and medical research. Here is an overview of some of the key biotech developments that have shaped the biotech industry in 2023. The 2023 biotech breakthroughs in Alzheimer’s treatments, oncology, and obesity as well as other areas demonstrates the industry’s commitment to tackling some of the most challenging health issues. As we move into a new year, the biotech sector continues to stand at the forefront of scientific breakthroughs, poised to deliver solutions that could transform lives and shape the future of healthcare.
[87] Applications and challenges of CRISPR-Cas gene-editing to disease ... — A variety of studies have applied CRISPR-Cas systems for effectively targeting different genes and have managed to prove the potential treatment ability for initiation or progression of lung cancer,64 breast cancer,65,66 and many other types of cancers.67–69 Meanwhile, the CRISPR-Cas system has been harnessed to serve as a powerful tool with the ability of unbiased screening of precision medicine including identification of new drug targets, biomarkers, and elucidation of mechanisms leading to drug resistance.70–72 In short, there are tremendous potential applications for CRISPR-Cas and their derivative systems (i.e. dCas9) due to the ability to accurately determine the underlying disease causes, genetic mutation variants, immunological regulatory factors, cell signaling mediators, and drug targets as well as drug molecules and therapeutics.
[88] Advances in CRISPR/Cas-based Gene Therapy in Human Genetic Diseases — Advances in CRISPR/Cas-based Gene Therapy in Human Genetic Diseases - PMC Advances in CRISPR/Cas-based Gene Therapy in Human Genetic Diseases Keywords: CRISPR/Cas, Gene editing, Gene therapy, Human disease, Genetic disease To date, three clinical trials aiming to treat patients with β-thalassemia and severe sickle cell disease by transfusion of CRIPSR/Cas9 edited CD34+ human HSCs (CTX001) have been initiated by CRISPR Therapeutics in 2018 and Allife Medical Science and Technology Co., Ltd in 2019 (Table 3). Similarly, CRISPR/Cas- induced NHEJ has been used to treat DMD in a DMD dog model after AAV-mediated systemic delivery of CRISPR gene editing components.
[89] Advances in vaccines: revolutionizing disease prevention — Advertisement Advances in vaccines: revolutionizing disease prevention Scientific Reports volume 13, Article number: 11748 (2023) Cite this article 1915 Accesses 1 Altmetric Metrics details Subjects Vaccines have revolutionized modern medicine by preventing infectious diseases and safeguarding public health. This Collection showcases cutting-edge research on advancements in vaccine development and their impact on disease prevention. The papers presented here report various facets of vaccine efficacy, immunological responses, and design, providing insight into future immunization strategies. Vaccines have long been credited as the most effective tool in preventing and managing infectious diseases.
[123] Molecules in Medicine: Personalised Therapies | Open Medscience — Molecules in Medicine: Personalised Therapies | Open Medscience The article concludes by reflecting on the future directions of molecular medicine, focusing on personalised medicine, advances in drug delivery, and the ethical challenges in this evolving field. The molecular approach to medicine encompasses understanding the molecular mechanisms of diseases, developing targeted therapies, and creating diagnostics that can detect disease at an early stage. Gene therapies and nucleic acid-based drugs target the genetic level of diseases. Cancer treatment has greatly benefited from molecular medicine, with targeted therapies providing more personalised and effective treatment options. Small molecules, peptides, proteins, and nucleic acids are at the forefront of this revolution, and emerging technologies like nanomedicine, gene editing, and RNA therapies hold immense potential.
[124] Advances in Molecular Medicine: Unravelling Disease Complexity and ... — The ability to classify diseases and stratify patients precisely, based on their molecular profiles, facilitates the implementation of tailored therapeutic approaches, thereby maximising treatment efficacy and minimising adverse effects. Molecular therapeutics describes a wide range of therapeutic approaches that utilise our understanding of molecular pathways, genetics, and biomarkers to develop targeted treatments for various diseases, including personalised medicine and targeting some infectious diseases. Beyond cancer, molecular therapeutics holds potential for managing autoimmune disorders, rare genetic diseases, and infectious diseases, heralding a new era of precision medicine with tailored treatments for individual patients. More research is required to improve our understanding and develop targeted treatments for UFs. The following three reviews discuss how new therapeutic strategies for cancer treatment, particularly targeted therapies, have improved patient survival.
[125] The Role of Molecular Biology in Modern Medicine - Sci Chores — Molecular biology plays a pivotal role in medicine by providing insights into the molecular basis of diseases and facilitating the development of innovative diagnostic methods and targeted therapies. With its capacity to analyze and manipulate genes and proteins, molecular biology has revolutionized the field of medicine, improving patient outcomes, and transforming healthcare practices. Advancements in molecular biology have led to the emergence of genetic medicine and personalized treatment approaches. In conclusion, molecular biology is a rapidly evolving field that has revolutionized medicine by providing insights into the molecular mechanisms of diseases and enabling personalized treatments. By addressing these challenges and embracing future directions, molecular biology holds the potential to further revolutionize medicine, improve patient outcomes, and pave the way for personalized and precision healthcare.
[134] Advances in drug delivery systems, challenges and future directions — Advances in drug delivery systems, challenges and future directions - PMC Recent drug delivery systems (DDS) are formulated using advanced technology to accelerate systemic drug delivery to the specific target site, maximizing therapeutic efficacy and minimizing off-target accumulation in the body. 104.Ziaie B., Baldi A., Lei M., Gu Y., Siegel R.A. Hard and soft micromachining for BioMEMS: review of techniques and examples of applications in microfluidics and drug delivery. 109.Sutradhar K.B., Sumi C.D. Implantable microchip: the futuristic controlled drug delivery system. 115.Hilt J.Z., Peppas N.A. Microfabricated drug delivery devices. The Application of Carbon Nanotubes in Target Drug Delivery Systems for Cancer Therapies; pp. 138.Zargar S.M., Hafshejani D.K., Eskandarinia A., Rafienia M., Kharazi A.Z. A review of controlled drug delivery systems based on cells and cell membranes.
[144] A genomic strategy for precision medicine in rare diseases: integrating ... — Given that 80% of rare diseases have a genetic component, delivering genomic information in a timely manner has proven to enhance clinical decision-making, improve patient outcomes, and facilitate personalized treatment strategies, ultimately leading to more effective management of complex diseases . To implement routine genetic testing for all inherited disorders included in the services portfolios of all public Andalusian hospitals, we designed the first version (D1) of an NGS custom designed panel called pRARE (Personalized Rare Diseases Exome), which was subsequently updated twice (D2 and D3, consecutively) with the purpose of improving coverage of the most in-demand groups of pathologies.
[145] Rare disease genomics and precision medicine — This review explores the role of genomics in rare disease research, the impact of large consortium initiatives, advancements in extensive data analysis, the integration of artificial intelligence (AI) and machine learning (ML), and the therapeutic implications in precision medicine. Although big data has been integrated in rare disease genomics, major barriers still need to be addressed, including difficulties in identifying causal variants and translating findings into clinical practice. AI and ML technologies contribute to rare disease research by assisting the analysis of vast amounts of genomic and clinical data to identify disease patterns, predict treatment outcomes, and develop personalized therapies, ultimately improving diagnostic accuracy and advancing drug development . The field of rare disease research has undergone significant advancements, driven by technological innovations in genomic sequencing, big data analytics, and AI.
[146] The Impact of Artificial Intelligence on Optimizing Diagnosis and ... — In rare disease management, AI contributes to precision medicine by utilizing extensive data from patient registries to uncover potential associations, thereby enhancing prevention, diagnosis, treatment, and monitoring based on individual genetic profiles . This narrative review article aims to comprehensively explore the role of AI and ML in improving the diagnosis and treatment of RDs. It covers the complexities of RDs, the importance of accurate diagnosis and tailored therapies, the historical evolution and recent advancements in AI/ML in healthcare, and their potential benefits and challenges. The review discusses how AI/ML uses genetic and clinical data for precise diagnosis, includes case studies of successful applications, and examines personalized medicine and drug discovery for RDs. Ethical considerations related to AI-driven treatment decisions are addressed, along with challenges such as data quality, algorithm interpretability, regulatory concerns, and AI/ML integration into healthcare systems.
[147] Integrating Genetic Data into Electronic Health Records: Medical ... — In the US, eMERGE (Electronic Medical Records and genomics) project was started in 2007 to integrate genomic data into EHRs and to use genetic test results in clinical and pharmaceutical research . In the first phase, a form was designed to extract the main requirements for integrating genetic data into EHRs. As a result, a list of items including data elements (patient's data, healthcare provider's data, clinical and genetic data), the main requirements for technical infrastructure, security issues, and the main functional requirements was developed based on the literature review . The results of the first phase of this study showed that the main requirements for integrating genetic data into EHRs could be categorized in four areas: data elements (patients', healthcare providers', clinical, and genetic data), technical infrastructure, security and functional requirements.
[165] Ethical issues in molecular medicine of relevance to surgeons — Four specific areas that are exemplary by presenting both major scientific and ethical challenges are briefly addressed: privacy of information, stem cells, gene therapy, and conflict of interest in biomedical research. Here we briefly address 4 important areas that are topical and relevant to surgeons as well as to molecular scientists: privacy of information; stem cells; gene therapy; and conflict of interest in biomedical research. As we move further into the age of molecular medicine, surgical patients with diseases such as breast cancer, myocardial ischemia and osteoarthritis (to name a few) stand to benefit enormously from recent advances in molecular biology such as genetic testing, stem cell research/manipulation and gene therapy. Ethical issues in human stem cell research.
[168] Informed consent for genetic testing in hematology — Using the example case of Mr. Smith, a man with newly diagnosed acute myeloid leukemia whose clinicians offer him genetic testing of the leukemia through a clinical trial, I highlight the challenges and controversies of informed consent for genetic testing, focusing on each consent element as it pertains to genetic testing in such a setting. Without question, however, as genetic testing becomes more common in both research and clinical practice in hematology, ensuring that patients provide informed consent for testing will become all the more important. As the role of genetic testing in hematology grows further, to provide optimal and equitable care to their patients, all hematologists must exhibit practical knowledge of the elements of informed consent as they relate to genetic testing in hematology.
[169] The Ethics of Consent in a Shifting Genomic Ecosystem - PMC — In our recent study of attitudes on the collection of genetic data and EHR data for research among individuals who identified as African American, Hispanic, Chinese, South Asian, and non-Hispanic white, our findings underscore the importance of trust for patients contemplating participation in genomic research and the need for public discussion about the collection of genetic data as compared with other patient information (88). This article describes consent for collecting genetic data and approaches for addressing ethical considerations in balancing privacy protections, risks, benefits, and fairness and equity in genetic research. J. Law Med. Ethics 46(1):110–18 [DOI] [PMC free article] [PubMed] [Google Scholar]
[170] The role of effective communication in achieving informed consent for ... — For consent to be valid, patients must first be given all the information they need about the proposed research to be able to decide whether they would like to take part. This material should be presented in a way that is easy for them to understand. This article explores the importance of communication in clinical research, and how more
[171] PDF — ©The Joint Commission, Division of Health Care Improvement deportation; and for some Asian immigrants, the patriarch or a male designated by the family must be consulted.13,14,15,16 Safety Actions to Consider: Health care organizations can improve the process of informed consent and enhance the safety of their patients by doing the following: • Promote the notion of informed consent as a process of effective communication between a provider and patient and not a signature on a form.17,18 • Have clear written policy on informed consent for care, including: o Procedures requiring written consent o Professional roles in the informed consent process o Use of qualified medical interpreters o The role of patients’ substitute decision makers o Timing of informed consent o Nature of a complete informed consent process o Documentation and verification process o Related tools and resources available for provider use to enhance the informed consent process • Provide a formal training program to physicians on effective provider-patient communication and shared decision-making and the impact on informed consent and patient safety.
[172] Informed Consent: When Patients Are Not Fully Informed of Risks — To mitigate these risks, it is crucial for healthcare providers to ensure that they obtain thorough and documented informed consent from their patients. By prioritizing informed consent, healthcare providers can avoid legal and regulatory repercussions while upholding ethical standards of patient care. By prioritizing transparency and thorough communication during the informed consent process, healthcare providers can build and maintain trust with their patients. By integrating technology into the informed consent process, healthcare providers can enhance patient understanding and engagement. Robert Peirce & Associates, P.C. At Robert Peirce & Associates, P.C., we understand the importance of informed consent and the need for patients to be fully informed about their treatment options and associated risks.
[183] Principles and Best Practices for Protecting Participant Privacy — This page provides a set of principles and best practices for creating a robust framework for protecting the privacy of research participants when sharing data under the NIH Policy for Data Management and Sharing (DMS). The DMS Policy is consistent with federal regulations for the protection of human research participants and other NIH expectations for the use and sharing of scientific data derived from human participants, including: NIH’s 2014 Genomic Data Sharing (GDS) Policy, the 2015 Intramural Research Program Human Data Sharing Policy, 45 CFR 46, and other applicable federal, Tribal, state, and local laws, regulations, statutes, guidance, and institutional policies that govern research with human participants. Supplemental Information to the NIH Policy for Data Management and Sharing: Protecting Privacy When Sharing Human Research Participant Data
[185] Guiding Principles for Sharing Clinical Trial Data — Moreover, sharing clinical trial data could potentially lead to enhanced efficiency and safety of the clinical research process by, for example, reducing unnecessary duplication of effort and the costs of future studies, reducing exposure of participants in future trials to avoidable harms identified through the data sharing, and providing a deeper knowledge base for regulatory decisions (Califf, 2013; Doshi et al., 2013; Eichler et al., 2012; Goldacre, 2013; IOM, 2013; Krumholz et al., 2014; Mello et al., 2013; Ross et al., 2012). Sharing of clinical trial data should be carried out in such a manner that it does not repeat, in the data sharing context, well-documented historical examples of imposing disproportionate risks of clinical research on vulnerable groups and thereby undermining the trust of those groups in the overall clinical trial process (Bioethics Commission, 2011; Emanuel et al., 2008; Jones, 2008; Wertheimer, 2008).
[186] Safeguarding Privacy in Genome Research: A Comprehensive Framework for ... — This paper presents a bidirectional framework for evaluating privacy risks associated with data shared (both in terms of summary statistics and research datasets) in genomic research papers, particularly focusing on re-identification risks such as membership inference attacks (MIA). A well-structured survey is a vital component of the proposed workflow, serving as the primary tool for collecting detailed information on the data sharing practices and privacy protection measures implemented by researchers in genomic studies. This case study illustrates the use of a structured workflow to evaluate the privacy risks associated with the sharing genomic research finding and statistics, particularly in the context of data sharing policies and re-identification risks. Case Study 2: Privacy Risk Evaluation in a Genomic Research that shared Both Raw Data and Statistics:
[196] Genome privacy: challenges, technical approaches to mitigate risk, and ... — In this article, we discuss clinical, technical, and ethical aspects of genome data privacy and confidentiality in the United States, as well as potential solutions for privacy-preserving genotype–phenotype linkage in biomedical research. As a result, in addition to widely discussed privacy risks (e.g., authorized re-identification, forensic or other law enforcement re-identification8,9), participants of human genome studies (HGSs) may also be subject to attribute disclosure risk even from what are labeled “de-identified data.”10 In response to this threat, the NIH shifted to a controlled-access model, which removes all aggregate data from open-access repositories to protect HGS participants against re-identification.11 The development of a well-balanced policy for genome and clinical data sharing requires joint efforts from technical, regulatory, and ethics communities, including experts in computer science, computer security, genetics, ethics, privacy law, and many other fields, to enable efficient genomic data analysis and record linkage in biomedical research, while respecting the privacy of individuals.
[198] Privacy and ethical challenges in next-generation sequencing — For these reasons, NGS in research and clinical contexts has raised concerns regarding data protection, informed consent, and return of results. With NGS moving increasingly into clinical applications, patients and institutions will need to consider how to inform patients of the privacy risks that might arise from reidentification of the data and the sharing of clinical genomic data for research purposes. Informed consent for genetic testing in clinical contexts generally involves informing patients of the risks and benefits of the testing, the implications of positive or negative results, limitations, alternatives, protections for information, future use of data and follow-up after testing. In particular, the use of NGS in clinical and research contexts raises ethical concerns in relation to privacy, machine learning techniques, informed consent, and return of results.
[199] Principles and Best Practices for Protecting Participant Privacy — This page provides a set of principles and best practices for creating a robust framework for protecting the privacy of research participants when sharing data under the NIH Policy for Data Management and Sharing (DMS). The DMS Policy is consistent with federal regulations for the protection of human research participants and other NIH expectations for the use and sharing of scientific data derived from human participants, including: NIH’s 2014 Genomic Data Sharing (GDS) Policy, the 2015 Intramural Research Program Human Data Sharing Policy, 45 CFR 46, and other applicable federal, Tribal, state, and local laws, regulations, statutes, guidance, and institutional policies that govern research with human participants. Supplemental Information to the NIH Policy for Data Management and Sharing: Protecting Privacy When Sharing Human Research Participant Data
[203] Exposomics: a review of methodologies, applications, and future ... — Exposomics is the emerging field of research to measure and study the totality of the exposome. Exposomics can assist with molecular medicine by furthering our understanding of how the exposome influences cellular and molecular processes such as gene expression, epigenetic modifications, metabolic pathways, and immune responses.
[205] Understanding the Impact of Genetics on Medicine — The field of genetics has revolutionized the way we approach medicine, allowing us to understand the role of genetic mutations and genes in disease diagnosis, treatment, and therapy. By studying genes and genetic variations, we can better understand disease susceptibility, develop targeted treatments, and improve overall patient outcomes. It allows for personalized medicine tailored to an individual’s genetic profile, helping to predict disease susceptibility, guide treatment choices, and develop targeted therapies. Genetics plays a crucial role in medicine as it helps us understand how certain diseases are inherited, identify potential genetic disorders in individuals, and develop personalized treatments and therapies based on an individual’s genetic makeup.
[206] Implementation and utilization of genetic testing in personalized medicine — Pharmacogenetics is the study of the genetic determinants of drug response variability, and increasing enthusiasm for implementing clinical pharmacogenetic testing is evidenced by the personalized medicine programs that are now preemptively genotyping germline pharmacogenetic variants1 and the recent availability of clinical practice guidelines when pharmacogenetic test results are available.2 Other developments supporting the implementation of pharmacogenetic testing include the recent availability of rapid sample-to-answer genotyping platforms that could potentially be used at the point-of-care3 and the increasing use of clinical decision support (CDS) for health care providers deployed through electronic health records (EHRs).4 This review aims to summarize the current state of the personalized medicine genetic testing field, with an emphasis on pharmacogenetic testing and clinical implementation.
[207] The rise of the genome and personalised medicine - PMC — As set out in the Annual report of the Chief Medical Officer 2016: Generation Genome_1 and the recent NHS England board paper _Creating a genomic medicine service to lay the foundations to deliver personalised interventions and treatments,2 the increasing ‘mainstreaming’ of genetic testing into routine practice and plans to embed whole genome sequencing in the NHS mean that the profile and importance of genomics is on the rise for many clinicians. Every human genome contains around 3–5 million genetic variants compared with the reference sequence. Genomic medicine has the capacity to revolutionise the healthcare of an individual with a rare disease or cancer by offering prompt and accurate diagnosis, risk stratification based upon genotype and the capacity for personalised treatments.
[210] AI and Genomic Data Security: Balancing Innovation and Privacy in ... — By striking a balance between innovation and privacy, we aim to provide a comprehensive framework for securing genomic data in the age of AI, ensuring that the benefits of precision medicine are
[221] Ethical considerations of gene editing and genetic selection — At the end of the summit, the organizing committee released a statement advising ongoing global engagement and discussion, and outlined their conclusions regarding gene editing: 97 “(i)ntensive basic and preclinical research is clearly needed and should proceed, subject to appropriate legal and ethical rules and oversight…”; “(m)any promising and valuable clinical applications of gene editing are directed at altering genetic sequences only in somatic cells… [and] they can be… evaluated within existing and evolving regulatory frameworks for gene therapy…”; and “(g)ene editing might also be used, in principle, to make genetic alterations in gametes or embryos…” The statement goes on to address the ethical, legal, and scientific questions surrounding germline editing that have yet to be answered, and warns: Tang L, Zeng Y, Du H, Gong M, Peng J, Zhang B, et al CRISPR/Cas9‐mediated gene editing in human zygotes using Cas9 protein.